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DopaminePrevious research shows consistent and marked executive function impairment in children with early and con-
tinuously treated phenylketonuria. This between groups analysis (phenylketonuria group vs sibling controls)
found no signiﬁcant differences in executive function (although adolescents with phenylketonuria performed
slightly worse than their siblings). Biochemical relationships with executive function were conﬁned to long-
term measures of high phenylalanine:tyrosine ratio exposure, as well as tyrosine exposure independent of phe-
nylalanine. This study suggests that early and continuously treated PKU results in non-signiﬁcant EF differences
(compared to siblings), although the inﬂuence of long-term exposure to poorermetabolic control is still evident.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The functional impact of executive function (EF) impairments in
children with early and continuously treated phenylketonuria (ECT-
PKU) has been well documented and quite marked, leading to an in-
creased risk of ADHDdiagnosis [1,2,7]. This study replicates previous in-
vestigations exploring the relationship between EF impairment and
biochemical control in this population [6]. Consistent with previous re-
search it was expected that 1) children with PKU would show greater
impairments than their siblings in EF, and that EF impairment would
bemore strongly associatedwith poorermetabolic control (higher phe-
nylalanine, phenylalanine:tyrosine ratio and lower tyrosine markers;
[3]).2. Method
2.1. Participants
Thirteen childrenwith classical PKUwere recruited as part of a larg-
er study from Royal Children's Hospital, Brisbane, Australia. All children, karen.sullivan@qut.edu.au
l@health.qld.gov.au (J. McGill).
. This is an open access article underhave ECT-PKU and Table 1 presents their biochemical data. The charac-
teristics of the 13 children with classical PKU were: seven male and six
female andmean age of 13.95 years (SD: 1.8 years; range: 10.26 years to
16.26 years). Nine siblings (6 male; 3 female) were assessed for be-
tween groups analyses. Their mean age at testing was 13.12 years
(SD: 3.4 years; range: 7.5 years to 17.58 years). Five siblings were
older than their sibling with PKU, and six were of the same gender.2.2. Materials
The Behaviour Rating Inventory of Executive Function (BRIEF) pro-
vides an ecologically valid measure of the manifestation of EF deﬁcits
in daily life e.g., impact on school work, family functioning and social re-
lationships [4]. The BRIEF was recommended by the Waisbren and
White [8] review as an appropriate test instrument for this population.
The Global Executive Composite (GEC; an overall score of EF impair-
ment) as well as working memory subscale were used in the analyses.
Working memory (WM) was also chosen given the consistent ﬁndings
that it remains an executive function most at risk in this cohort [2].2.3. Procedure
Parents ﬁlled out the BRIEF questionnaire concurrent with neuro-
psychological test administration as part of a larger study whilst on-
site at the Royal Children's Hospital.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1







Lifetime 438 (149) 97 (17) 7.4 (4.2)
226–735 67–121 3.6–19.5
b12 years 415 (146) 95 (15) 7.1 (4.1)
226–706 67–114 3.6–18.9
Concurrent 713 (273) 105 (40) 7.9 (4.4)
200–1200 45–170 1.3–16
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Raw scores were converted to t-scores to account for variations in
age and sex. A t-score of 50 represents average function, with a
deviation of 10 representing the equivalent of one standard deviation;
higher t-scores indicate higher levels of impairment. A deviation of 15
(i.e., a t-score of 65 or above) is considered by the BRIEF scoringmanual
as clinically signiﬁcant and in need of further investigation.
3. Results
An independent samples t-test was conducted to test for signiﬁcant
differences in GEC and WM between children with classical PKU and
their siblings and no signiﬁcant difference was found (Table 2).
3.1. Biochemical markers associated with BRIEF t-scores
Correlations between lifetime, b12 year, and concurrentmeasures of
phenylalanine, tyrosine, and the phe:tyr ratio as well as the two mea-
sures of EF were generated to test for associations between biochemical
markers in the classical PKU cohort and parent report of EF impairment
(GEC and WM). t-Scores were used to account for age and sex varia-
tions. One-tailed Pearson's rwas used to assess signiﬁcance in all corre-
lations given the directional nature of the hypotheses. Three signiﬁcant
correlations were observed: lifetime tyrosine and GEC (r=−.546, p=
.027), tyrosine b12 years and GEC (r =−.500, p = .041) and lifetime
phenylalanine:tyrosine ratio and GEC (r= .478, p= .049). These corre-
lations indicated that lower lifetime tyrosine and lower tyrosine prior to
12 years were associated with an increased parent report of global EF
impairment, and that a higher lifetime phenylalanine:tyrosine ratio
was associatedwith an increased parent report of global EF impairment.
WM showed no signiﬁcant associations with biochemistry; likewise no
measure of phenylalanine showed any signiﬁcant associations with EF.
4. Discussion
In this sample, the BRIEF did not detect signiﬁcant differences be-
tween children with classical PKU and their siblings, although t-scores
indicate descriptively higher (worse) EF in the PKU group compared
to their siblings. Given the small sample size our studywas likely under-
powered, previous PKU-sibling research using larger samples has
shown small but statistically signiﬁcant differences (in the region of
one third of a standard deviation worse), and our data demonstrates
similar differences [5,9].Table 2
Differences in BRIEF T scores between children with classical PKU and sibling controls.
Mean SD Signiﬁcance
PKU —WM 60.1 14.3
Sibling —WM 56.0 12.2 p= .511
PKU — GEC 56.1 11.8
Sibling — GEC 53.1 8.1 p= .542
Note: WM—working memory and GEC— global executive composite.Three signiﬁcant correlations between children with PKU and their
phenylalanine:tyrosine ratio and tyrosine independent of phenylala-
nine were observed. The failure to a) ﬁnd signiﬁcant between-groups
differences and b) signiﬁcant correlations on the WM scale is likely
due to the small sample size. Correlations between tyrosine and EF im-
pairmentwere in the expected direction (negative), in that lower levels
of lifetime (and b12 years) tyrosine were associated with higher levels
of EF impairment. Although not all correlations between tyrosine and
GEC/WM were statistically signiﬁcant, all tyrosine correlations were in
a negative direction, further indicating a trend towards low levels of ty-
rosine associated with increased EF impairment.
A high lifetime phenylalanine:tyrosine ratio was also found to corre-
late positively with GEC, in that the higher the ratio, the higher the level
of parent-reported impairment. No correlations between phenylalanine
on its own and EF were observed in this sample. This study has also
found an association between tyrosine levels on their own
(i.e., independent of phenylalanine) and EF.
In all, these results provide support that poorer metabolic control
underpins EF impairment in this population [3]. Phenylalanine expo-
sure was not shown to be associatedwith EF deﬁcit in this sample, rath-
er, the strongest associations between biochemistry and reported EF,
involved long-term tyrosine deﬁcit or a high phenylalanine:tyrosine
ratio. This is likely because the samplewas early and continuously treat-
ed, with reasonable phenylalanine compliance across their lifetime.
Nonetheless, subtle inﬂuences of poorer metabolic control on EF
remained evident.
Acknowledgements and conﬂicts of interest
The authors would like to thank the Royal Children's Hospital Foun-
dation for their generous grant (10242; Allied Health Research Project
Grant) worth $24,491. The authors have no conﬂicts of interest to
report.
References
[1] G.L. Arnold, C.J. Vladutiu, C.C. Orlowski, E.M. Blakely, J. DeLuca, Prevalence of stimu-
lant use for attentional dysfunction in children with phenylketonuria, J. Inherit.
Metab. Dis. 27 (2004) 137–143, http://dx.doi.org/10.1023/B:BOLI.0000028725.
37345.62.
[2] S.E. Christ, S.C.J. Huijbregts, L.M.J. de Sonneville, D.A. White, Executive function in
early treated phenylketonuria: proﬁle and underlying mechanisms, Mol. Genet.
Metab. 99 (Suppl) (2010) S22–S32, http://dx.doi.org/10.1016/j.ymgme.2009.10.007.
[3] A. Diamond, M.B. Prevor, G. Callender, G.P. Druin, Prefrontal cortex cognitive deﬁcits
in children treated early and continuously for PKU, Monogr. Soc. Res. Child Dev. 62
(1997) 1–208.
[4] G.A. Gioia, P.K. Isquith, S.C. Guy, L. Kenworthy, Behaviour Rating Inventory of Execu-
tive Function, Psychological Assessment Resources Inc, Lutz, FL, 2000.
[5] Koch, R., Azen, C., Friedman, E. G., &Williamson, M. L. (1984). Paired comparisons be-
tween early treated PKU children and their matched sibling controls on intelligence
and school achievement test results at eight years of age. J. Inherit. Metab. Dis., 7,
86–90, http://dx.doi.org/10.1007/BF01805813.
[6] R. Sharman, K. Sullivan, R. Young, J. McGill, Biochemical markers associated with ex-
ecutive function in adolescents with early and continuously treated phenylketonuria,
Clin. Genet. 75 (2009) 169–174, http://dx.doi.org/10.1111/j.1399-0004.2008.01101.
x.
[7] Simon, E., Schwarz, M., Roos, J., Dragano, N., Geraedts, M., Siegrist, J.,…Wendel, U.
(2008). Evaluation of quality of life and description of the sociodemographic state
in adolescent and young adult patients with phenylketonuria (PKU). Health and
Quality of Life Outcomes, 6, 25, http://dx.doi.org/10.1186/1477-7525-6-25.
[8] S.E. Waisbren, D.A.White, Screening for cognitive and social-emotional in individuals
with PKU: tools for use in the metabolic clinic, Mol. Genet. Metab. 99 (Suppl 1)
(2010) S96–S99, http://dx.doi.org/10.1016/j.ymgme.2009.10.006.
[9] J. Weglage, B. Funders, B. Wilken, D. Schubert, K. Ullrich, School performance and in-
tellectual outcome in adolescents with phenylketonuria, Acta Pediatrica 82 (1993)
582–586, http://dx.doi.org/10.1111/j.1651-2227.1993.tb12759.x.
